Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04943744 · ClinicalTrials.gov registry record · Early Phase 1
Gastrointestinal STRING Test With Oral Immunotherapy
A Early Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT04943744: Clinical Trial Early Phase 1 study, sponsored by Stanford University.
NCT04943744 is a Early Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04943744, a Early Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.
Interventions
- BIOLOGICAL omalizumab
- DEVICE Entero-tracker
- BIOLOGICAL dupliumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-17 |
| Est. Completion | 2024-05-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04943744
The ClinicalTrials.gov registry entry for NCT04943744 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which omalizumab is the first listed.
NCT04943744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04943744 about?
NCT04943744 is a clinical study titled "Gastrointestinal STRING Test With Oral Immunotherapy". This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of ...
What is the current status of trial NCT04943744?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2021-05-17. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT04943744?
The interventions under investigation include: omalizumab (BIOLOGICAL), Entero-tracker (DEVICE), dupliumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04943744?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.